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Abstract
Many factors contribute to a company's decision to launch a product in a new market.
The company must be able to identify a clinical need that the product will address and the
market must be willing to pay for the new technology. This thesis explores the clinical
and market need for an improved shock monitoring technology.
Shock occurs when there is not enough blood flow to adequately perfuse the body's
organs. In the United States, about 500,000 patients go into sudden shock every year and
half of these patients die. For millions of additional patients, shock is the final stage of a
terminal disease. Despite advances in many other areas of medicine, shock continues to
be a serious, life threatening condition. It is my hypothesis that the limitations of the
current monitoring technologies contribute to the high mortality rate associated with
shock.
In my research, I examined the currently available monitoring technologies and their use
for the diagnosis and resuscitation of shock patients. I conducted an extensive review of
the scientific literature to identify the limitations of the current monitoring technologies
and to understand the challenges of diagnosing and treating shock. To supplement my
research, I interviewed clinicians who treat shock patients and scientists who are trying to
develop new shock monitoring technologies.
The clinicians confirmed that there is a critical need for improved shock monitoring
technologies. However, for a new shock monitor to be successful, it will need to address
the limitations of the current technologies. A well-designed clinical trial will be
necessary to demonstrate that the new technology is sensitive and specific, clinically
relevant, and easy to use.
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Glossary of Terms
Afterload: The resistance against which the heart must eject its volume of blood. It is
closely related to the aortic pressure.
Anasarca: An accumulation of fluid in the peripheral tissues that results in extreme
generalized edema.
Cardiac Index (CI): A measure of cardiac performance that relates cardiac output (CO)
to body surface area (BSA). CI = CO / BSA
Cardiac Output (CO): Volume of blood being pumped by the heart per minute. A
normal adult heart pumps about 5 L of blood per minute. CO = SV * HR (SV - Stroke
Volume and HR - Heart Rate)
Central Venous Pressure (CVP): A direct measure of blood pressure in the thoracic
vena cava and an estimation of the right atrial pressure.
Crystalloid: Fluid, used during resuscitation, including lactated Ringer's solution,
normal saline, Ringer's acetate, and balanced electrolyte solution.
Colloid: Fluid, used during resuscitation, including albumin, 5% plasma protein fraction,
synthetic starches, and dextrans.
Hypoxia: A condition of inadequate oxygen in the blood, either generally or locally
Ischemia: A restriction in blood supply, generally due to factors related to the blood
vessels
Lactate: Produced by exercising muscles from the conversion of glucose and
metabolized by red blood cells metabolize. Lactate is released into the blood and
transported to the liver where it is converted back into glucose. In homeostasis, the
production and destruction of lactate is balanced. However, when tissue is damaged,
lactate production outpaces lactate clearance.
Mean Arterial Pressure (MAP): The average arterial pressure during a single cardiac
cycle, which is considered to be the closest approximation of the perfusion pressure
through the organs. MAP can be calculated from the systolic and diastolic blood
pressures, but the relationship changes with changes to the heart rate. MAP = (CO *
SVR) + CVP
Negative Predictive Value (NPV): A statistical measure of the proportion of patients
with a negative test result who are correctly diagnosed as not having a particular
condition. NPV = TN / (TN + FN), where TN is the True Negative (patients without the
disease who receive a negative test result) and FN is the False Negative (patients with the
disease who receive a negative test result).
Oliguria: Decreased production of urine
Positive Predictive Value (PPV): A statistical measure of the proportion of patients
with a positive test result who are correctly diagnosed as having a particular condition.
PPV = TP / (TP + FP), where TP is the True Positive (patients with the disease who
receive a positive test result) and FP is the False Positive (patients without the disease
who receive a positive test result).
Preload: Pressure stretching the ventricle of the heart after passive filling and atrial
contraction, but before ventricular contraction.
Retroperitoneum: The anatomical space located behind the abdominal cavity.
Sensitivity: A statistical measure of how well a binary classification test correctly
identifies that a patient has a particular condition. Sensitivity = TP / (TP + FN), where
TP is the True Positive (patients with the disease who receive a positive test result) and
FN is the False Negative (patients with the disease who receive a negative test result).
Specificity: A statistical measure of how well a binary classification test correctly
identifies that a patient does not have a particular condition. Specificity = TN / (FP +
TN), where TN is the True Negative (patients without the disease who receive a negative
test result) and FP is the False Positive (patients without the disease who receive a
positive test result).
Systemic Vascular Resistance (SVR): The resistance of blood flow offered by the
peripheral vasculature; affected by changes in blood vessel diameter and changes in
blood viscosity. SVR = (MAP - CVP) / CO
Tissue Perfusion: The volume of blood that flows through a unit mass of tissue per unit
time; presented in physiologic units of milliliters of blood per 100 grams of tissue per
minute.
Chapter 1: Introduction
Importance of Blood Flow
Blood flow is necessary to sustain all living tissues in the body. The heart pumps
approximately five liters of blood through ten miles of blood vessels about 1,000 times a
day [13]. Blood flows from the heart, through the aorta, and into the arteries, the
arterioles, and finally the capillaries. The capillary network is responsible for carrying
blood to within 0.2 mm of every living cell in the body, delivering oxygen, nutrients, and
hormones to the tissues of the Tothe From theheart heart
body and removing carbon
dioxide, ammonia, and other
waste. The figure to the right
illustrates some of the important
features of the vasculature,
including the relative sizes and
structures of the arteries,
arterioles, capillaries, venules,
uter Layer
ODe
and veins [17].
Blood flow can be described in terms of its systemic and regional properties. Systemic
blood flow parameters, such as blood pressure and heart rate, provide a reasonable
indication of a patient's general health, but they do not describe blood flow through the
capillaries, so they are unable to predict oxygen delivery to the body's tissues. Tissue
perfusion can be defined as "the rate at which the quantity of blood in a given mass or
volume of tissue is replenished at the level of the capillary network" [35]. While tissue
perfusion does not precisely describe oxygen delivery, by describing blood flow through
the capillaries rather than through the arteries or veins, it more closely approximates
oxygen delivery to the body's tissues. The amount of tissue perfusion depends on the
patient's systemic vascular resistance, cardiac output, and effective volume of blood.
Systemic vascular resistance is determined by the length and diameter of the blood
vessels and the viscosity of the blood. Cardiac output is determined by the heart rate and
stroke volume. Effective blood volume refers to the quantity of blood and other fluids
that are circulating through the arteries, veins, and capillaries. Inadequate tissue
perfusion can be due to a decrease in systemic vascular resistance, a decrease in cardiac
output, a decrease in blood volume, or a combination of the three parameters.
The effects of inadequate tissue perfusion are reversible if blood flow is restored quickly.
However, inadequate perfusion over time can result in permanent cell injury because
prolonged hypoxia causes cells to alter their metabolic processes. In hypoxic states, cell
membranes stop functioning properly, leading to intracellular edema and/or the leakage
of intracellular contents into extracellular spaces. These cellular changes eventually
cause cell death and organ damage. Over time, hypoxia can result in multiple organ
failure and death [4].
There is no gold standard for determining if the tissues of the body are being oxygenated.
Rather, physicians use a combination of different methods to assess systemic blood flow
and estimate tissue perfusion in high risk patients. Some of these methods include:
* Physical evaluation of patient (mental status, skin color, temperature,
sweating, capillary refill time): The clinician's eye is one of his or her most
valuable tools provided that it is integrated with a lifetime of experience.
Hypoxic patients can progress from a normal mental state to anxious, agitated,
lethargic, and eventually comatose [4]. As the peripheral vasculature constricts,
the skin becomes pale and cool and the capillary refill time increases.
* Blood pressure: A decline in blood pressure, without any other known
explanation, is an indication that the body's tissues might be deprived of oxygen.
However, blood pressure is only useful if the clinician can determine the patient's
baseline pressure because a low blood pressure could be normal for one patient
and catastrophic for another. Clinicians will typically intervene if the patient's
systolic blood pressure is less than 90mmHg.
* Heart rate: When the body's tissues are not being adequately oxygenated, the
heart pumps faster.
* Respiratory rate: When the body's tissues are not being adequately oxygenated,
the respiratory rate increases.
* Urine output: There is a minimum amount of urine that the body should excrete
to ensure the removal of toxic byproducts. Since the kidneys are susceptible to
decreases in blood flow, a decline in urine output can indicate that the body's
tissues are becoming ischemic.
* Blood gases (i.e. pH, lactate): The normal pH of the blood is about 7.8, but
when the body's tissues are hypoxic, they are forced to undergo anaerobic
metabolism, which decreases the pH. Anaerobic metabolism also creates lactate
as a byproduct.
The physical evaluation and blood pressure provide crude, but very useful information
about a patient. While not sufficient at detecting small changes in tissue oxygenation,
they provide a preliminary indication of a patient's status. Trends in these parameters
can also be very helpful in determining if a patient is getting better or worse or how a
patient is responding to therapy. Increases in heart rate and respiratory rate are two of the
body's first efforts to compensate for inadequate oxygenation. Urine output gives the
clinician a picture of what is happening in the kidney, one of the body's vital organs. If
the kidney becomes ischemic, the body stops producing urine, which alerts the clinician
to intervene. Blood gases provide the closest approximation to what is happening at the
tissue level, but they are a late warning sign of tissue hypoxia.
While each of these parameters provide information that enables a clinician to better treat
the patient, they do not identify the underlying condition that is causing the hypoxia, so
they do not provide a means of preventing patients from going into shock. They are also
not adequate at determining when a patient has been sufficiently resuscitated, so
clinicians typically rely on a combination of the available parameters.
What is Shock?
Clinical Problem
Clinicians have been describing shock for hundreds of years. For example, in 1872, Dr.
SG Gross defined shock as a "manifestation of the crude unhinging of the machinery of
life" [24]. Today's definitions of shock are less poetic and more descriptive of the
underlying mechanisms. Dorland's Medical Dictionary defines shock as "a condition of
profound hemodynamic and metabolic disturbance characterized by failure of the
circulatory system to maintain adequate perfusion of vital organs" [3]. The Advanced
Trauma Life Support Manual defines shock as "an abnormality of the circulatory system
that results in inadequate organ perfusion and tissue oxygenation" [24].
There are many underlying medical conditions that can cause a patient to go into shock.
As a result, shock has been divided into subtypes based on the general cause of the
inadequate tissue perfusion.
* Hypovolemic Shock: Hypovolemic shock is caused by an inadequate volume of
blood due to hemorrhage or a loss of fluid. This is the most common cause of
shock and it often develops after a trauma or surgery.
o "Shock is a complication of many traumatic conditions and is the cause of
up to half of all deaths from trauma: 40 percent due to acute hemorrhage
and up to 10 percent due to multiple organ failure long after the initial
cause of shock has been controlled" [4].
* Cardiogenic Shock: Cardiogenic shock is caused by a cardiac defect that prevents
the heart from pumping sufficiently. Cardiogenic shock can also be described as
obstructive shock when it is caused by mechanical factors that interfere with the
filling or emptying of the heart or large vessels. The mechanisms of cardiogenic
shock include impaired myocardial contractility, abnormalities of cardiac rhythm,
and cardiac structural disorders. Cardiomyopathies, arrhythmias, mechanical
defects, and obstruction can all result in cardiogenic shock, but the most common
cause is heart attack.
o There are about 280,000 cases of cardiogenic shock per year in the United
States [13].
o Less than 10% of patients with a heart attack will develop cardiogenic
shock, but the mortality rate for these patients is about 50% [19].
Distributive Shock: Distributive shock is caused by a decrease in systemic
vascular resistance (vasodilation) most often due to sepsis, anaphylaxis, or
another condition that activates the systemic inflammatory response. Rarely,
distributive shock can be caused by a severe injury to the brain or spinal cord.
This form of shock is called neurogenic shock and it results from the sudden loss
of autonomic and motor reflexes below the injury level, causing the vessel walls
to relax. Distributive shock can also be the result of hypovolemic or cardiogenic
shock that has persisted for several days.
o "Sepsis affects 500,000 people in the US every year; about half of them
develop septic shock, and 125,000 die from it" [13].
o Sepsis is the leading cause of death in the noncoronary intensive care unit,
accounting for over $17 billion in healthcare costs [32].
Classification of Shock [25]
Type of Shock
Parameters Hypovolemic Cardiogenic Obstructive Distributive
Preload, filling pressures, end-diastolic volumes T. , It
Pump, cardiac output I
Afterload, systemic vascular resistance
Systemic oxygen delivery T
Systemic oxygen consumption T1I
Systemic oxygen extraction ratio T I I
Global oxygen balance, SvO2 or ScvO2* I I I '
* SvO2, mixed venous oxygen saturation; ScvO2, central venous oxygen saturation.
In the United States, 500,000 people go into sudden shock every year and about half of
these patients die [13]. For millions of additional patients, shock is the final stage of a
terminal disease. While physicians have understood the causes of shock for many years,
prevention and treatment continue to be extremely difficult. In fact, many of the
diagnostic techniques and therapeutic interventions have not changed significantly in the
last 20 years.
Regardless of the underlying cause, many of the clinical symptoms of shock are similar.
These can include hypotension, cold or clammy skin, oliguria, a decline in mental status,
and metabolic acidosis. These symptoms develop as the patient progresses from pre-
shock to shock and finally to end-organ dysfunction and death [6]. In pre-shock, the
body is able to compensate for the reduction in perfusion. The extent and duration of
compensation varies significantly depending on the age and health of the patient.
Clinical symptoms may be entirely absent during this phase. When a patient enters the
shock phase, the body is no longer able to compensate for the inadequate perfusion.
During the end-organ dysfunction phase, irreversible organ damage occurs.
Shock is a life threatening condition and must be managed with immediate intervention.
Dr. R. Adams Cowley, founder of the R Adams Cowley Shock Trauma Center and
Maryland EMS System in Baltimore, Maryland, is credited with developing the concept
of the "Golden Hour" of shock management. He explained:
"There is a golden hour between life and death. If you are critically injured you
have less than 60 minutes to survive. You might not die right then; it may be
three days or two weeks later - but something has happened in your body that is
irreparable" [37].
While the early phases of shock are reversible, late shock is not reversible. Therefore,
early care that is provided in the emergency room plays a critical role in determining a
patient's outcome. In the case of hypovolemic and septic shock, fluids are administered
intravenously to restore tissue perfusion. However, there is a threshold for reperfusion.
If too much fluid is administered, the patient can sustain additional organ damage from
over-resuscitation. For example, if the vasculature has been vasoconstricted for a period
of time, a sudden restoration of blood flow will provides a means of distributing the
metabolic toxins that accumulated in the hypoxic tissue [4]. Acute renal failure and
pulmonary edema are two injuries that can result from the distribution of metabolic
toxins and inflammatory mediators [8]. The timing and aggressiveness of fluid
resuscitation should also be considered in patients that are actively bleeding because it
can increase bleeding, by diluting the clotting factors and increasing the blood pressure
[11].
Market Opportunity
In 2004, Dorland Healthcare Information projected that the US patient monitoring market
would reach $4.3 billion in 2008 [34]. While the total market is growing, much of that
growth is driven by self-monitoring devices used in the home and the emergence of
alternate sites of care, including outpatient surgical centers.
The US hospital-based vitals signs monitoring market generated $804.4 million in 2004
[9]. Vital signs monitors measure a variety of different parameters, including the
patient's temperature, respiratory rate, pulse rate, capnography, blood pressure, and blood
oxygenation. Critical care units are responsible for over 50% of the revenue that is
generated from patient monitor sales [9]. ICU patients only occupy about 10% of
inpatient beds, but they account for almost 30% of acute care hospital costs, or $180
billion per year in the United States [32]. The patient monitoring market is fairly
saturated, so current development efforts are primarily focused on replacing the current,
invasive technologies with non-invasive technologies that measure similar parameters.
Philips Medical Systems and GE Healthcare are the leading players, representing over
70% of the hospital vital signs patient monitoring market [9].
Hemodynamic monitoring represents a growing segment of the patient monitoring
market. In the US, the market forecast for hemodynamic monitoring, which includes
pulmonary artery catheters as well as non-invasive and minimally invasive technologies,
is projected to reach revenues of $154 million by 2012 [32]. The non-invasive and
minimally invasive segment is projected to grow at a compound annual growth rate of
20% over the next 5 years, while pulmonary artery catheter sales are projected to
decrease from $98.1 million in 2007 to $85.7 million in 2012 [32]. The use of pulmonary
artery catheters has been decreasing for several years. In fact, between 1993 and 2004,
PAC use declined 65% [33]. At the annual meeting of the Society of Critical Care
Medicine in February 2008, clinicians stressed the need for improved hemodynamic
monitoring technologies for the diagnosis of sepsis and shock [32].
US Market Forecast for Noninvasive and Minimally Invasive Cardiac Output
Monitoring Systems [32]
Objective of Thesis
Despite advances in many other areas of medicine, shock continues to be a serious, life
threatening condition. This raises a number of issues and questions. For example, what
drives the high mortality rates of shock patients? Are the diagnostics or therapeutics
insufficient? Is the process or approach to treating patients insufficient? Does the natural
history of the condition cause patients to deteriorate before a clinician is able to
intervene? It is my hypothesis that the limitations of current monitoring technologies
contribute to the high mortality rate associated with shock.
My goal is to characterize the current monitoring and management techniques and to
analyze the need for an improved monitoring technology. Prior to conducting my
Year Sales Annual Change
2006 $22.5 million
2007 $31.5 million 40.0%
2008E $38.0 million 20.6%
2009E $45.0 million 18.4%
2010E $52.0 million 15.6%
2011E $60.0 million 15.4%
2012E $69.0 million 15.0%
CAGR 20.5%
(2006- 2012E)
analysis, I identified two relevant patient groups, those at risk of going into shock and
those that are being resuscitated from shock.
In order to better ascertain if the current monitoring technologies are sufficient, I define
the standard of care for monitoring patients that are at risk of going into shock, and for
monitoring patients that are being resuscitated from shock. I expect that there is not one
universal standard of care, but rather, heterogeneity in the protocols used at various
hospitals and by different clinicians.
To assess my hypothesis, I empirically ask the following questions.
* How do clinicians manage patients that are at risk of going into shock?
* How do clinicians manage patients that are in shock?
* What monitoring technologies are used and in what combination?
* Under what conditions do clinicians intervene?
* What goes wrong? Why? How often?
* What do clinicians do when something goes wrong and what is the outcome?
* Would an earlier warning of a patient's entry into shock change the management
or outcome?
o How much earlier would be necessary?
o How would the management or outcome change?
* Would an improved measurement of tissue perfusion change the management or
outcome of patients that are in shock?
o What kind of improvement is necessary?
o How would the management or outcome change?
Chapter 2: Methodology
Review of Scientific Literature
To identify the limitations of the current monitoring technologies and assess the need for
an improved tissue perfusion monitoring device, I conducted an extensive review of the
leading scientific journals. I identified the challenges of preventing and managing shock
as well as the currently available monitoring technologies, their uses and their limitations.
I also conducted research on technologies that have been developed, but not widely
adopted, to help identify the challenges that a new technology would undoubtedly face.
Interviews
While my research was useful in identifying monitoring technologies and describing
some of their limitations, I needed to understand which devices are actually used and in
what combinations. I also needed to understand how clinicians perceive the limitations
of the available monitoring technologies. I therefore interviewed clinicians to determine
how they use the available monitoring technologies to manage patients that are either at
risk of going into shock or are being resuscitated from shock. In addition to clinicians, I
interviewed scientists who are working to improve the management of shock patients by
developing new monitoring technologies or by improving the use of the current
monitoring technologies.
Developing the Interview Guide
I created a detailed interview guide to focus my interviews on the key issues. A
brainstorming session with my thesis advisors, a BEP Advisory Board member, and a
former BEP student served as a starting point for the interview guide. In addition to
focusing the interview questions on the most relevant topics, I also designed the guide to
support a one hour interview. I circulated a draft interview guide to the group for
feedback prior to finalizing the questions and structure.
I designed the questionnaire to include a majority of open ended questions. While it can
be challenging to aggregate the responses to open-ended questions, this format was the
most appropriate for my needs because it did not constrain the responses of my
interviewees. It also allowed the clinicians to raise issues that I had not previously
considered. I avoided leading questions and I allowed my interviewees to speak freely,
rather than stopping them after their initial responses. At the conclusion of each
interview, I asked the clinicians to rate their overall satisfaction with the current
monitoring technologies and the value of a tissue perfusion monitor.
I scheduled my first interview with a clinician who was interested in shock and familiar
with my thesis project. This enabled me to pilot test the questions and the overall
structure of the interview guide. After the first interview, I made several minor changes
to the structure of the guide. The final interview guide can be found in Appendix A.
Selection of Interviewees
I set a goal of interviewing 10-15 clinicians from at least five institutions. This relatively
small number of interviews would not be sufficient for a robust statistical analysis, but it
provides the diversity that I need to supplement my research, further characterizing shock
monitoring. I acknowledge that a more extensive study might be necessary to justify a
significant investment in the development of a new monitoring technology.
I leveraged my network to schedule interviews with clinicians at several hospitals.
Additionally, since shock patients are treated in the emergency room, the intensive care
unit, and the operating room, I selected clinicians that monitor patients and provide care
in each of these environments. By interviewing a diverse group of clinicians, I
minimized the risk of hospital-specific or environment-specific perspectives. However, I
deliberately selected a majority of anesthesiologists. One of the primary roles of an
anesthesiologist is to monitor the vital signs of patients to make sure that their health
status is stable or improving. Since anesthesiologists spend a significant amount of time
monitoring patients for the signs of shock, they were ideal interview candidates. I
requested interviews with twelve clinicians at seven hospitals and three scientists and was
successful in scheduling interviews with the following twelve individuals.
Anesthesia and Critical Care at Massachusetts General Hospital,Michael Bailin, M.D. Boston, MA
Critical Care Medicine at Dartmouth-Hitchcock Medical Center,Howard Corwin, M.D. Lebanon, NH
Vice Chair of Anesthesiology at University of MassachusettsMark Dershwitz, M.D., Ph.D. Medical Center, Worcester, MA
Chief of Trauma Anesthesiology at University of MarylandRichard Dutton, M.D., M.B.A. Medical Center, Baltimore, MD
Anesthesia and Critical Care at Massachusetts General Hospital,Stuart Forman, M.D. Boston, MA
Anesthesiology, Perioperative, and Pain Medicine at Brigham and
Women's Hospital, Boston, MA
General and Gastrointestinal Surgery at Brigham and Women'sEdward Kelly, M.D. Hospital, Boston, MA
Hepatobiliary Surgery & Liver Transplantation and General
Surgery at Lahey Clinic, Burlington, MA
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To provide some additional context for my interviews, I spent time in an intensive care
unit, several operating rooms, and a trauma center. I accompanied Dr. Luca Bigatello,
Director of Critical Care, as he conducted rounds in the intensive care unit at
Massachusetts General Hospital. I joined Dr. Michael Bailin as he oversaw the
anesthesiology team in several operating rooms at Massachusetts General Hospital. Dr.
Richard Dutton and his anesthesiology staff gave me a tour of the Shock Trauma Center
at the University of Maryland Medical Center.
Chapter 3: Monitoring Technologies
Shock Monitoring Technologies
Patient monitoring is extremely important in the intensive care unit, the operating room,
and the emergency department. Vital signs, including body temperature, blood pressure,
respiratory rate, and pulse rate, are continuously monitored for all critically ill patients.
Changes in any of these parameters can indicate a decline in the patient's health status
and the need for intervention. However, while these parameters provide a general
indication of the patient's status, they are not always sufficient to determine if a patient is
at risk for going into shock. Physicians rely on data from a combination of different
monitoring technologies to determine if a patient is going into shock, and to manage the
treatment of shock patients.
Arterial Catheter
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glucose, blood gases, and coagulation parameters. Lactate is a particularly important
parameter in shock patients because it gives an indication of the severity and duration of
shock. Lactate can also be used to guide resuscitation because lactate clearance indicates
that the patient is responding to the therapeutic intervention [20].
In 2005, Edwards launched the FloTrac system, which uses an arterial catheter and
continuous self-calibration to provide cardiac output, stroke volume, stroke volume
variation, and systemic vascular resistance. The system achieved sales of almost $30
million in 2007 [32].
In the United States, about 8 million arterial lines are placed every year [29]. Arterial
catheters are commonly used because they provide valuable hemodynamic information
and serious complications from placement are extremely rare. However, arterial lines
take time to insert. This can limit the use of arterial lines, especially during the early
monitoring of shock patients that occurs in the emergency room.
Central Venous Catheter
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Central venous catheterization provides a means of continuously
measuring superior vena caval oxygen saturation, which is a
surrogate marker of mixed venous oxygen saturation. Mixed
venous oxygen saturation is probably the most specific marker for
tissue perfusion, but it requires the use of a pulmonary artery catheter. There is some
evidence that controlling resuscitation to achieve target superior vena caval oxygen
saturation values can improve survival [22, 25]. However, the relationship between
superior vena caval oxygen saturation and mixed venous oxygen saturation varies
significantly between healthy volunteers and critically ill patients. This makes it difficult
to determine an appropriate target for superior vena caval oxygen saturation and prevents
clinicians from being able to confidently estimate mixed venous oxygen saturation in
critically ill patients.
Echocardiography
Echocardiographic techniques use standard ultrasound to provide
two-dimensional images of the heart. These images provide
clinicians with information about the size, shape, and pumping
function of the heart. Transesophageal echocardiography is often
used during cardiac surgery because it provides many different
views of the heart. A specialized probe, with an ultrasound transducer, is placed in the
patient's esophagus. Since the heart is located within millimeters of the esophagus,
transesophageal echocardiography provides much clearer images than a traditional
echocardiogram. Viewing the heart enables the clinician to determine if there are any
structural abnormalities that could impair blood flow. The addition of a Doppler
transducer to the echocardiographic device enables the measurement of the blood
velocity.
Esophageal Doppler Monitor (EDM)
The esophageal Doppler monitor provides 
a minimally invasive
and low cost method of continuously 
monitoring hemodynamic
variables. The parameters that can be derived 
from EDM include
peak velocity 
in the descending 
aorta flow 
time and heart 
rate.
These variables can be used to calculate cardiac output, stroke volume, and cardiac index.
The EDM is inserted similarly to a nasogastric tube and has been used to guide fluid
management in the OR and ICU [20]. In May 2007, CMS confirmed that it would
provide coverage on a national basis for the use of esophageal Doppler monitoring of
blood circulation [32].
Foley Catheter
A Foley catheter is a thin, sterile tube that is inserted into the
bladder to drain urine. While the Foley catheter does not measure
or estimate blood flow, the device is important because it enables
clinicians to measure the amount of urine being produced by the
kidneys. Since a decline in urine output is associated with inadequate perfusion of the
kidneys, the Foley catheter provides a surrogate marker for renal perfusion. Moreover,
since the kidneys are considered to be vital organs, their perfusion status can help
clinicians to understand the status of other abdominal organs.
Gastric Tonometry
Gastric tonometry is a method of indirectly measuring the pH of
the gastric intramucosal cells to determine if and when these
cells become hypoxic. The gastric tonometer is inserted into the
stomach through the nasogastric or orogastric route. After
insertion, a small amount of saline is pumped into the balloon
and left to equilibrate. A sample of arterial blood is taken and the blood and aspirated
saline are analyzed in a blood gas analyzer. The intestinal pH is calculated from the
saline PCO2 and the arterial bicarbonate concentration.
This measurement is relevant because a low gastric mucosal pH could provide an early
warning that a patient is going into shock. Gastric intramucosal pH could also be used to
determine if a patient has been sufficiently resuscitated. There is a general consensus that
a low gastric intramucosal pH is associated with a poor outcome. However, while
treatment with fluids raises the pH, the clinical significance of this increase is
questionable because there is no evidence that it improves patient outcomes [7].
Additionally, the device can take up to 30 minutes to insert and calibrate, which poses a
significant logistical burden. Based on these findings, many scientists question whether
intramucosal pH is a good measure of intestinal mucosal oxygenation and the gastric
tonometer has not been widely adopted. It has recently been shown that sublingual
mucosal carbon dioxide correlates well with gastric mucosal carbon dioxide and illness
severity in septic patients [20]. Since these devices are much easier to use than gastric
tonometers, they may become more commonly utilized to monitor shock patients.
Pulmonary Artery Catheter (PAC)
When the pulmonary artery catheter, also called the Swan-Ganz catheter, was first
developed in the late 1960s, it provided data that was not otherwise available. As a
result, it experienced rapid, widespread adoption. However, by the late- 1980's,
physicians and scientists became concerned about the PAC's invasiveness and its still
unknown therapeutic utility.
Today, the pulmonary artery catheter provides a means of continuously measuring
temperature, heart rate, mixed venous saturation of oxygen, cardiac output, right
ventricular ejection fraction and end-diastolic volume, central venous pressure, and
pulmonary arterial pressure [22]. Mean arterial pressure, which is believed to reflect the
perfusion pressure of the vital organs, can be calculated from the measured indices.
Mixed venous saturation is probably the most specific marker for tissue perfusion, but
calibration can be difficult for the patients that need it the most. As a result, it has never
been validated in trauma patients. However, it can be used in septic shock patients
because for these patients, resuscitation efforts do not interfere with efforts to control the
source of the sepsis.
Despite the vast amount of data that is available from a pulmonary
artery catheter, there is little evidence that the information leads to
improvements in patient outcome. In fact, there have been five
large randomized trials of PAC use and none of them has
demonstrated a significant clinical benefit to patients [27]. Additionally, there are risks
associated with the insertion of a PAC. These risks include arterial puncture, infection,
arrhythmias, and pneumothorax. While several studies have concluded that the risks
outweigh the benefits, a randomized controlled trial by Richards et al. found that "clinical
management involving early use of a PAC was not associated with significant changes in
mortality and morbidity among patients with shock" [25]. The use of pulmonary artery
catheters continues to be a controversial issue among the academic and medical
communities and in recent years, the utilization of PACs has declined significantly.
Pulse Oximetry
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and arterioles in the subcutaneous tissue by illuminating the skin with the light from a
light emitting diode (LED) and measuring the amount of light that is either transmitted or
reflected to a photodiode.
Pulse oximeters are often placed on the finger or ear, but in cases of shock, when blood
flow in the periphery can be reduced, the pulse oximeter can be placed on the head.
Typical uses for pulse oximeters include the monitoring of heart rate, respiration, depth
of anesthesia, and hypo- / hyper-volemia. The detection of a pulse is critical for the pulse
oximeter to function. While pulse oximeters are beneficial, they do not provide a
complete measure of circulatory sufficiency. For example, if there is insufficient blood
flow or insufficient hemoglobin in the blood, the tissue can suffer hypoxia despite high
oxygen saturation.
Limitations of Current Technologies
Questionable Impact on Outcomes
One of the most serious limitations in the currently available technologies is a lack of
useful data to quantify the therapeutic benefits and impact on outcomes. While studies
have been and continue to be published, there is significant controversy surrounding their
conclusions. For several of the available technologies, there are strong opponents and
proponents who site conflicting studies to defend their position [7, 26, 28, 24]. Gastric
tonometry and pulmonary artery catheters are two of the most controversial technologies
for shock monitoring and as a result, they are in limited use today.
Systemic, Not Regional Blood Flow
Another limitation of the currently available technologies is that they measure systemic,
rather than regional, blood flow. Since the body is able to compensate for a certain level
of cardiac insufficiency, systemic measures may not provide the earliest signal that a
patient is at risk of going into shock. Additionally, during resuscitation, the systemic
measures may return to normal before the tissues have been sufficiently perfused.
Therefore, it is likely that an accurate measure of regional blood flow would provide a
faster and more sensitive indication of a patient's entry into shock or of a patient's
adequate resuscitation from shock. However, there are limitations to monitors that
measure regional blood flow. While the heart, brain, and abdominal organs are
understood to be the body's vital organs, it is not clear which of these organs, if any,
would be the most appropriate for measuring regional blood flow.
Technologies in Development
Over the past 10 or 15 years, several new hemodynamic monitoring technologies have
become available and a few of them, including gastric tonometry and PACs inserted into
the hepatic vein, have focused on regional blood flow. However, despite the perceived
improvements of measuring regional rather than systemic blood flow, the technologies
have failed to gain widespread market acceptance [22]. The most common reason why
these technologies failed is because they were not associated with improved outcomes.
Monitoring for the sake of monitoring is not useful. Any new monitoring technology
must be associated with an improved outcome, either by altering the natural progression
of the disease or by altering the treatment. Today, the quest for an improved monitoring
technology continues.
Thermal Diffusion
11L ___ 1- - - ~ ~ ~ _~ ~___I~ -- - - ~--
Hemedex has developed a tissue perfusion monitor that uses a
proprietary thermal 
diffusion technology 
to provide a continuous
and accurate measure of absolute regional blood flow, in
milliliters per minute per 100 grams of tissue, at the capillary
level. The device consists of a patient monitor, a cable, and a
probe. The probe, which is 1 mm in diameter, is inserted into -"
the tissue of interest for up to 10 days. The device measures the energy needed to
maintain a temperature differential between two temperature sensors and a complex
computer algorithm uses this energy measurement to calculate the blood flow in the
volume surrounding the probe.
The Hemedex tissue perfusion monitor has FDA approval for "extravascular monitoring
of microcirculation blood flow in buried tissues" and is currently being marketed to
neurosurgeons. The probe costs about $1,000 and is being used to monitor brain
perfusion during cerebral aneurysm surgery, during recovery from subarachnoid
hemorrhage when the patient is at risk of vasospasm, and following traumatic brain
injury. While research on shock patients is not yet available, data from animal
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experiments indicate that this technology could provide an earlier warning of a patient's
entry into shock and improved monitoring during resuscitation from shock.
Near Infrared Spectroscopy
Near infrared spectroscopy is a non-invasive monitoring technology that continuously
assesses tissue oxygen saturation, using wavelengths of near infrared light to illuminate
the tissue below a sensor placed on the skin. Tissue oxygen saturation measurements
differ from pulse oximetry measurements in that pulse oximetry measures the systemic
oxygen saturation of the arterial blood [36].
HutchinfQn Trchnnl oiie haq a commPrciallv availhable
spectroscopy system that uses near infrared spectroscopy to
determine the average tissue oxygen saturation across skin,
fat, and muscle, using proprietary algorithms. It permits the
continuous, noninvasive measurement of tissue hemoglobin
oxygen saturation and has been shown, in clinical trials, to be more reliable than base
deficit and SvO2 as an index of hemorrhagic shock [2].
Reflectance Medical is developing a non-invasive technology to monitor tissue pH, tissue
oxygen saturation, and hematocrit for the early detection of hemorrhagic and septic
shock. The company uses a continuous-wave spectroscopic instrument to determine
muscle oxygen saturation. In a recent trial, Reflectance Medical demonstrated that its
device was able to detect patients in mild and moderate shock while the Hutchinson
Technologies' device was only able to detect severe shock [30]. Much of the company's
development has been in collaboration with the United States Army. The U.S. Army is
interested in identifying patients before they go into shock because once they go into
shock, it is often too late.
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Chapter 4: Managing Patients in Shock
In managing patients in shock, the clinician's primary goal is the restoration of tissue
perfusion and oxygenation. However, the means of restoring tissue perfusion differ
depending on the underlying mechanism of shock. Hypovolemic and distributive shock
are typically managed with fluid resuscitation while cardiogenic shock is often managed
by administering agents that increase the pumping function of the heart.
Advanced Trauma Life Support
Trauma and post-operative bleeding are two of the leading causes of hypovolemic shock.
In fact, about 40% of the deaths from injury are due to shock from blood loss [4]. The
American College of Surgeons has developed a curriculum, Advanced Trauma Life
Support (ATLS), which has become the standard for diagnosing and managing trauma
patients around the world [4]. The ATLS guides the clinician to provide the ABCs
(airway support, mechanical ventilation, and circulatory support), if necessary, and then
check for any neurologic disability or other injuries. A bolus of fluid is administered to
determine if the patient is a "responder," a "transient responder," or a "nonresponder."
As a general rule, responders are not actively bleeding while transient responders and
nonresponders are actively bleeding. In the case of transient responders or
nonresponders, the clinician must quickly identify the source of the blood loss and look
for other causes of shock, including a high spinal cord injury, tension pneumothorax, and
cardiac tamponade. For all massive trauma patients, the ATLS curriculum provides
guidance on looking for blood loss. Computed tomography imaging is one of the most
useful tools for identifying the source of the blood loss. The ATLS also guides the
clinician through the resuscitation process.
Resuscitation Protocols
The following diagram provides an algorithm for the resuscitation of a patient in shock
[16]. In patients with tachycardia and/or hypotension, clinicians begin with the ABC's,
securing the airway, assuring that the patient is breathing, and providing any necessary
circulatory support. If the vital signs are still unstable, the clinician is directed to insert a
central line and begin monitoring the patient's central venous pressure. If the central
venous pressure is low, the clinician should administer fluids, either crystalloid or blood
depending on the patient's hematocrit, until the central venous pressure rises. If the vital
signs no not improve, the clinician should consider inserting a pulmonary artery catheter
to measure the cardiac index and pulmonary capillary wedge pressure. Depending on the
values of these parameters, the clinician should administer additional fluids or an
inotropic agent, which increases the contractility of the heart.
Source: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J:
Harison' s Principles of Internal Medicine, 17th Edition: http://www.accessmedicine.com
Copyright @ The McGraw-Hill Companies, Inc. All rights reserved.
VS (vital signs), HR (heart rate), SBP (systolic blood pressure), W/U (work up), CVP
(central venous pressure, ECHO (echocardiogram), PAC (pulmonary artery catheter),
CI (cardiac index - L/min per m2), PCWP (pulmonary capillary wedge pressure -
mmHg), SVo2 (saturation of hemoglobin with 02 in venous blood), SVRI (systemic
vascular resistance), RVEDVI (right-ventricular end-diastolic volume index)
Choice of Resuscitation Fluids
"The Advanced Trauma Life Support (ATLS) protocol of the American College of
Surgeons recommends the liberal use of isotonic crystalloid to correct hypotension in
bleeding trauma patients" [12]. However, published data neither supports nor rejects this
recommendation. While the liberal administration of fluids may increase blood pressure,
it may also increase the bleeding. In some cases, the administration of crystalloids can
result in anasarca, an accumulation of fluid in the peripheral tissues. If this occurs,
colloids (typically albumin) can be used as resuscitation fluids. The data is inconsistent,
but there is evidence that albumin can harm a subgroup of trauma patients, while it may
have helped a subgroup of septic patients. Red blood cells, platelets, and plasma are also
administered, but they are not necessary if the patient's hematocrit is greater than 30.
Chapter 5: Interview Results
While the strengths and weaknesses of the current shock monitoring technologies are
described in the literature, the perceptions of clinicians and scientists are best gathered
through in-person conversations. The interviews provide an opportunity to translate the
limitations of the current technologies into a better understanding of the clinical need for
improved shock monitoring. By speaking with clinicians about their challenges,
companies can learn how to better position their products for market adoption.
What is Shock?
Clinicians are in general agreement about the definition of shock. Shock is a clinical
state including hypotension and persistent, insufficient tissue oxygenation. It is broadly
defined and can result from many different diseases and injuries. In all cases,
vasodilation (low systemic vascular resistance), problems with the pumping function of
the heart, or a low volume of circulating blood cause a patient to develop the clinical
signs of shock. However, there is not a universal threshold for changes in any of these
parameters that will result in shock. In fact, the body is able to compensate for many of
the causes of low blood pressure, maintaining adequate tissue oxygenation. Today,
clinicians use a systolic blood pressure of less than 90 mmHg as the threshold for shock.
Who is at Risk?
Shock describes a set of symptoms rather than an underlying condition. The importance
of this becomes very clear when clinicians describe the types of patients that are at risk of
going into shock. These patients include everyone in the operating room and intensive
care unit, all trauma patients, and anyone with sepsis, anaphylaxis, spinal cord injury,
liver disease, kidney disease, or heart disease. While shock can be broken down into
different types that describe the mechanism (hypovolemic, cardiogenic, distributive), it is
often difficult to determine which type of shock a patient is developing or at risk of
developing since the signs and symptoms are similar.
In the OR, there is a reluctance to diagnose a patient as going into shock. One clinician
explained that there is a medical liability associated with a particular diagnosis and the
patient's subsequent outcome. Another clinician explained that a diagnosis of shock is
not very meaningful because it does not describe the underlying mechanism of disease.
And finally, since a diagnosis is not necessary to write an order for fluid, clinicians often
begin treatment for patients that are going into shock before formally diagnosing them.
Clinicians consider a number of factors when determining a patient's risk of developing
shock. The body's natural resistance to shock is determined by the patient's age and
general health status. The magnitude of initial insult and complexity of surgical
procedures are also important considerations. For example, a patient with acute
appendicitis is not likely to go into shock provided that he or she arrives at the hospital
within a short period of time. However, a patient with a perforated appendix has a higher
risk of going into shock because of the increased inflammation throughout the body. And
an 80 year old patient with a perforated appendix for two days has a very high risk of
going into shock. Clinicians must assess the health risks of each patient and adjust the
subsequent monitoring and management to reflect these risks.
While a clinician may be hesitant to diagnose a patient that is going into shock, there are
Diagnosis Related Groups (DRGs) for shock. Diagnosis Related Groups are used by the
Centers for Medicare and Medicaid Services (CMS) to classify hospital cases into
categories based on their expected hospital resource use. DRGs are also used to
determine how much CMS will pay the hospital for each patient. DRG 785.51 is the
code for cardiogenic shock and 785.59 is the code for other shock without mention of
trauma. There are also Medicare Severity-Diagnosis Related Groups (MS-DRG). These
codes are categorized to indicate if there is a Major Complication/Comorbidity (MCC), a
Complication/Comorbidity (CC), or a Non-Complication/Comorbidity. Additional
factors complicate the coding and reimbursement that a hospital will receive. For
example, effective 10/1/08, Medicare will not reimburse for a higher-paying DRG that is
the result of complications or comorbidities that are hospital-acquired and preventable
[10]. It is likely that this policy change will decrease the number of patients that are
diagnosed as going into shock, especially when the condition is believed to be transient.
How are Shock Patients Managed?
The management of shock patients primarily occurs in the emergency room, the
operating room, and the intensive care unit, but for some patients, it can begin in the
ambulance. For trauma patients, the early management that occurs in the ambulance and
ER is the most critical predictor of the patient's outcome. The time sensitive nature of
shock management led to the concept of the "Golden Hour" [37]. In some cases, the
patient's outcome is determined before he or she arrives at the hospital.
The management of a shock patient depends, in part, on the natural history of the
patient's underlying disease or injury. For example, if a patient arrives at the emergency
room in shock, the clinician will focus on resolving the underlying injury or disease,
providing only enough supportive care to delay the tissue injury that would result from
inadequate perfusion. Once the source of the patient's injury has been resolved, the
clinician will focus on resuscitation. In the operating room and the intensive care unit,
clinicians have access to extensive monitoring technologies, so a decline in the patient's
status can be detected quickly. In theory, this enables the clinician to intervene before the
patient enters the advanced stages of shock.
What are the Current Monitoring Technologies and How are they Used?
Most monitoring technologies measure general vital signs rather than specific shock
parameters. While there are many technologies that measure or estimate surrogates for
blood flow and tissue health, no one surrogate provides a complete picture of tissue
oxygenation. As a result, clinicians use several of the available monitoring technologies
in combination. In the emergency room, the focus is on easy to use, non-invasive
technologies that do not require complex configuration. Blood pressure, heart rate, and
pulse oximetry are the most common monitoring technologies used in the ER. In the OR
and ICU, more complex monitoring technologies can be used because there is more time
to insert and configure the monitors and the patient is typically in a more stable condition.
The most common technologies that are used to monitor patients at risk of shock or being
resuscitated from shock include:
* BP Cuff - cuff inflates every 4-5 minutes, measuring a patient's blood pressure
* EKG - continuously measures heart rate
* Arterial Catheter - blood gases (pH, lactate), continuous BP
* Foley Catheter - urine output
* Pulse Oximeter - pulse rate, % of bound hemoglobin (indicates oxygenation of
arterial blood)
While the monitoring technologies listed above are the most common, there are other
complementary technologies that can be used in higher risk patients. The Swan-Ganz or
Pulmonary Artery Catheter is the most interesting of these technologies because until
recently, it was widely used to monitor shock patients. The Swan-Ganz provides stroke
volume, cardiac output, and mixed venous oxygen saturation, but its use is associated
with substantial risks, including a risk of puncturing the artery or causing an arrhythmia.
Additionally, the use of a Swan-Ganz catheter has not been shown to improve patient
outcomes. There is also some data indicating that Swan-Ganz use has lead to doctors
making the wrong clinical decisions [1]. For example, clinicians might be tempted to
treat a low cardiac output when the low cardiac output is actually fine for a particular
patient. While the Swan-Ganz provides clinicians with additional information, that
information is only valuable if it leads to better patient management. Mixed venous
saturation, a measure of how much oxygen is being extracted from the blood, is a
surrogate for what is happening at the tissue level. Today, this parameter is only
available to clinicians if they are using a Swan-Ganz catheter. However, Central Venous
Catheters provide a means of continuously measuring the superior vena cava oxygen
saturation, which is a surrogate marker of mixed venous oxygen saturation. Central
venous catheters provide a less risky alternative for estimating tissue oxygenation.
There are other monitoring technologies that are only used when the clinician is
concerned about the pumping function of the patient's heart. The transesophageal
echocardiogram provides two-dimensional views of the patient's heart, so the clinician
can observe the filling and pumping functions. It can be used when the heart is at risk
and a pulmonary artery catheter is contraindicated. It is often used during open heart
surgery. The transesophageal Doppler measures blood flow through the aorta, so it can
be used to estimate cardiac output.
What Parameters are Most Useful in the Management of Shock Patients?
Despite the vast array of complex monitoring technologies available, clinicians rely most
heavily on their basic clinical tools and judgment. For example, several clinicians
indicated that their eyes are their most valuable tool. The clinical examination of a
patient, especially if the patient is awake and conscious, can provide a significant amount
of information regarding the patient's status. In sepsis, a decline in mental status is often
the first sign that a patient is going into shock. Pain, fever, skin turgor and pallor are also
critically important. Blood pressure, heart rate, respiratory rate, and the percentage of
bound hemoglobin provide the next level of information. These parameters are most
valuable when they are observed in relation to one another and when trends from baseline
can be observed. Urine output is probably just as important as the basic hemodynamic
parameters because there is a threshold of urine production below which a patient is
considered to be in trouble. And finally, clinicians discussed the value of the more
invasive hemodynamic parameters, including lactate, pH, sodium bicarbonate, and
central venous oxygen saturation. These parameters are believed to be better surrogates
for tissue oxygenation than blood pressure, heart rate, and respiratory rate. While they
were willing to discuss the most valuable parameters available through current
monitoring technologies, several clinicians pointed out that there is no good technology
for detecting organ hypoperfusion. Tissue oxygenation and tissue pH would be the ideal
parameters for managing shock patients.
What are the Limitations of the Current Technologies?
According to the clinicians interviewed, there are three primary limitations of the current
monitoring technologies. First, the current technologies measure or estimate surrogates
of blood flow rather than measuring tissue perfusion. As a result, clinicians do not know
if their therapeutic interventions are helping the patient. They can increase blood
pressure, but there is no indication that an increase in blood pressure translates to an
increase in tissue perfusion. Second, the current technologies are not able to detect when
the body's natural compensatory efforts are no longer sufficient. Clinicians are tempted
to intervene early to prevent the patient from entering advanced shock, but these
interventions do not take into account the body's natural ability to compensate for
moderate hypoxia. And finally, most of the available technologies are invasive, non-
continuous, and complex. Emergency room clinicians are the most concerned about the
invasiveness and complexity of the current monitoring technologies because these
limitations are deterring their use in the ER.
As a result of these limitations, clinicians make treatment decisions based on incomplete
information. Interviewees suggested that there is a tendency to over-treat rather than
waiting to determine if the body will be able to compensate, yet there is limited data
available to assess whether the benefits of over-treatment outweigh the risks.
What are the Therapeutic Interventions?
Clinicians are challenged to determine when to intervene therapeutically. In theory,
clinicians should intervene when the patient's body is no longer able to compensate for a
particular insult and the body's tissues start to become hypoxic. However, the cruder the
monitoring technology, the more likely a clinician is to intervene at the wrong time.
Additionally, each patient's threshold for a particular parameter depends on the patient's
age, genetics, and general health status. To further complicate the therapeutic
intervention, the clinician must balance the need to treat the underlying disease or injury
with the need to support the delivery of oxygen to the body's tissues.
Clinicians typically treat shock patients with crystalloid or colloid solutions if the patient
is believed to be hypovolemic, and with vasoconstrictive drugs if the patient is believed
to have low systemic vascular resistance. However, the underlying mechanism is not
always understood and it is generally believed that it is safer to administer fluid than
vasoconstrictive drugs. As a result, clinicians typically give a small amount of fluid
initially and wait to see how the patient responds before providing additional
interventions. Crystalloid is administered first and it is sufficient in most patients.
Colloid is sometimes administered if the patient becomes edematous because studies
have indicated that colloid is retained in the circulation while crystalloid solutions leak
out of the capillaries and into the interstitial space [12]. Clinicians typically give the
patient fluid until it is no longer effective or until the patient's central venous pressure
rises or there is a clinical response. If there is no response, or the response is not
sufficient, clinicians may add a vasopressor. Several clinicians mentioned the concept of
"filling the tank before you squeeze." This refers to giving fluid before administering
vasopressors. This is important because vasoconstricting a patient who is hypovolemic
can lead to increased tissue injury by making it even more difficult for the body to pump
blood to the peripheral tissues.
In distributive shock, the blood vessels are dilated, which results in low systemic vascular
resistance. This vasodilation results in a significantly larger volume of distribution, on
the order of 30L as compared to 5L for a healthy patient. Not surprisingly, the "normal"
volume of circulating blood is not sufficient to oxygenate the body's tissues in a
vasodilated patient. Early fluid resuscitation is extremely important for these patients,
but understanding the cause of the vasodilation is also important. In sepsis, finding the
source of the infection can be a significant challenge. Clinicians describe the treatment
of septic shock by breaking it into therapeutic emergencies and diagnostic dilemmas. In
a therapeutic emergency, the clinician must drain the abscess and administer broad
spectrum antibiotics before the organism has been identified. Once the organism has
been cultured, the antibiotics can be adjusted to better target the infection. If the patient
is not in immediate danger, the clinician can culture the organism before choosing the
appropriate antibiotic.
In hypovolemic shock, the patient has lost blood, but the pumping function of the heart is
normal and the volume of distribution is normal. The source of the blood loss must be
identified and resolved before the clinician can administer large quantities of fluid. In the
early management, clinicians administer just enough fluid to stop the decline of the
patient's status and hopefully prevent damage to the tissues. In most cases of
hemorrhagic shock, vasopressors are not helpful because the patient is already in a
vasoconstricted state. Rather, clinicians administer fluid and anesthesia, which has the
effect of vasodilating the patient. The goal is to move the patient from a state of low
blood pressure and vasoconstriction to a state of low blood pressure and vasodilation.
This facilitates the delivery of oxygen to all of the body's tissues rather than only
preserving the blood flow to the central organs. Once the source of the bleeding has been
resolved, the clinician can increase the fluid administration, which should bring the blood
pressure back into the normal range.
In cardiogenic shock, fluid should not be administered because it will overload an already
weakened heart. In a person with a compromised heart, additional fluid can lead to
congestive heart failure. In practice, this is extremely rare because clinicians typically
administer fluid slowly and make sure the patient is responding favorably before
administering more fluid. The treatment for cardiogenic shock focuses on resolving the
cardiovascular injury. This might involve performing minimally invasive surgery like
angioplasty to open a blood vessel, conducting open heart surgery to repair a defect, or
administering therapies designed to increase the pumping function of the heart.
During fluid resuscitation, clinicians must determine when to administer crystalloids or
colloids and when to administer blood products. The maximum allowable blood loss can
be calculated for a particular patient to ensure that hemoglobin and hematocrit levels
remain above an appropriate threshold. Hematocrit can drop to about 7 or 8 and
hemoglobin can drop to about 3 or 4 without causing secondary tissue injury. However,
clinicians typically administer blood products when the hematocrit drops below 30. For
actively bleeding patients, protocols are in place to provide a standard approach to fluid
resuscitation. If a patient is actively bleeding, clinicians give a 6:6:1 ratio of red cells to
plasma to platelets.
The most common endpoints of resuscitation are identical to the most useful parameters
for diagnosing shock. These parameters include blood pressure, heart rate, lactate, and
pH. About two thirds of bleeding patients have a low blood pressure and a high heart
rate. If a patient's blood pressure improves in response to fluid resuscitation, it usually
means that the bleeding has stopped. If the blood pressure gets worse or stays the same,
it usually means that the patient is still bleeding. Base deficit and pH provide an
instantaneous state of shock while lactate indicates how long and how severely a patient
is in shock. Lactate is currently the gold standard for resuscitation, but a change in the
negative trend of any of these parameters typically indicates an improvement in the
patient's shock status.
What Goes Wrong?
The most significant problems that occur while monitoring and managing shock patients
are the result of a misdiagnosis, a misinterpretation of the data, or some other form of
mismanagement. These problems can lead to the wrong clinical decisions. For example,
problems with cardiac function can be missed and unsuspected volume loss can
accumulate in the retroperitoneum, the abdomen, the chest, or the pelvis. Additionally
clinicians can be misled by what appears to be normal vital signs. Since the current
monitors measure surrogates, normal values can disguise an underlying pathology. For
example, young, healthy people have strong compensatory mechanisms designed to
protect the critical organs during a loss in circulating volume. These compensatory
mechanisms can preserve "normal" vitals, including blood pressure and heart rate, even
when the patient has lost or is continuing to lose significant amounts of blood.
In addition to the challenges of monitoring and managing shock patients, clinicians also
worry about the natural history of the underlying disease or injury. In patients with
hemorrhage, clinicians are not always able to control the bleeding. Treatment of septic
shock relies on the resolution of the underlying infection, which in turn depends on the
age and health of the patient and the characteristics of the bacteria. If a patient is in
shock when he or she arrives at the emergency room, the patient's outcome may have
already been determined. The clinicians provide supportive care while attempting to
resolve the underlying injury. The goal of the supportive care is to avoid additional
damage, allowing the body to recover, but recovery is not always possible. If the patient
has been in shock for too long, critical organs such as the brain, heart, kidneys, liver, or
gut, may have been without oxygen for too long. In these cases, the patient can
experience multiple organ failure and die.
Problems can also occur after the clinician resolves the underlying condition and
resuscitates the patient. Systemic Inflammatory Response Syndrome (SIRS) can develop
in trauma and sepsis patients. In SIRS, patients lose fluid from the central circulation to
the periphery because the capillaries become leaky. SIRS has a 50% mortality rate and
no one knows how to treat it. Even if SIRS is avoided, a patient can develop organ
failure several days after being fully resuscitated. The mechanism is not clear, but it is
likely that the organs suffered more hypoxia than they could withstand.
How has the Management of Shock Patients Changed Over Time?
The management of shock patients has changed significantly over time. Interviewees
described these developments as changes in the approach to shock management, changes
in monitoring technologies, and changes in therapeutic interventions.
Approach to Shock Management
Clinicians now have a better understanding of the mechanisms of shock and the
mechanisms of the patient's underlying disease or injury. They have learned that an
increase in tissue oxygenation, not a particular blood pressure or heart rate, should be the
goal in shock management. Ten years ago, if a patient's blood pressure was low, the
clinician would administer fluid and a vasoconstrictor until the blood pressure returned to
normal. However, this often resulted in extreme edema and it sometimes resulted in
ischemic peripheral tissues that would require amputation. Now, clinicians administer a
smaller amount of fluid, keeping patients relatively dry; a vasoconstrictor is not
administered until after the patient has received fluid. The pendulum is swinging, but
both approaches are probably over-reactions. In trauma, clinicians now give the body
time to compensate for the injury by vasoconstricting and clotting. Administering fluid
dilutes the blood, making it more difficult for the body to perform these important
compensatory functions. For this reason, clinicians try to keep the composition of the
blood as close to physiologically normal as possible. To do this, they follow a 6:6:1
protocol that recommends the administration of equal amounts of red blood cells and
plasma and the occasional administration of platelets.
Significant improvements have been made in treating the end stages of shock. Mortality
in the ICU is still as high as 80%, but patients are rarely dying from the late
complications of shock. However, very little has changed in the early management of
shock. The biggest change involves the role of the paramedic. Paramedics used to "stay
and play," performing limited interventions to stabilize the patient. Now, paramedics are
instructed to "load and run," minimizing the time it takes to transport a patient to the
emergency room [14]. This is another pendulum swinging from one extreme to the other
and it is likely that the ideal approach would fall somewhere in the middle. Despite all of
the changes, clinicians still struggle with the challenge of identifying the root cause of
shock, especially in sepsis, and balancing source control with resuscitation.
Monitoring Technologies
In the medical community, it is common for technologies to go in and out of favor as
clinical experience accumulates. Ten years ago, there was some interest in capnography,
a monitoring technology that measures the concentration or partial pressure of carbon
dioxide in the respiratory gases and provides an indirect measure of cardiac output. The
device was fairly reliable, but extremely cumbersome to insert. As a result, it is no
longer used. The Swan-Ganz or pulmonary artery catheter is another technology that has
gone out of favor over the last few years. Data emerged that questions the impact of the
Swan-Ganz catheter on patient outcomes. Since there are also risks associated with the
insertion of a pulmonary artery catheter, its use has declined significantly over the least
few years.
There are several promising new technologies that could have a significant impact on the
monitoring and management of shock patients. For example, the transesophageal
echocardiogram allows clinicians to observe the pumping function of the heart. This
provides an approximation of cardiac output, but it does not completely replace the data
available from a pulmonary artery catheter. Arterial waveform is also being used to
calculate cardiac output, primarily in patients with cardiogenic shock. Clinicians now
have more options for minimally invasive and non-invasive testing of hemodynamic
variables. There are more blood tests, including pH, lactate, and triponin, and point-of-
care analytical devices provide a means of testing the patient's blood at the bedside. This
bedside testing is not widely used, but it could increase the utility of blood gases in the
management of shock patients. There are also new technologies, including near infrared
spectroscopy and thermal diffusion, designed to provide information about what is
happening at the tissue level. While clinicians would value this tissue information, the
technologies are still unproven and the interviewees wonder if they will have an impact
on patient outcomes.
Therapeutic Interventions
The therapies that clinicians use to treat shock patients have changed very little. For
patients with hemorrhage, there are new products available to help patients clot. With
regards to vasopressors, dopamine is no longer used and vasopressin is now the
vasopressor of choice. While the therapies have not changed significantly, the ways in
which clinicians use the therapies has changed. I have discussed these changes in the
Approach to Shock Management section.
Overall Satisfaction
I asked each clinician to rate their satisfaction with the technologies available for
monitoring shock patients. Several clinicians are reasonably satisfied with the
monitoring of patients that are at risk of shock, but the majority of clinicians interviewed
are extremely dissatisfied. In contrast, there is a wide range of satisfaction levels with the
monitoring of patients that are being resuscitated from shock.
In monitoring patients at risk of shock, the mean satisfaction level is 2.9 out of 7 and the
standard deviation is 1.1. For patients that are being resuscitated from shock, the mean
satisfaction level is 3.6 out of 7 and the standard deviation is 1.6. While the means and
standard deviations are fairly similar, the distribution of responses indicates that there are
important differences in the monitoring of these patient populations.
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One of the clinicians stated that if you understand physiology, you only need the
measurements of blood pressure, heart rate, and blood gases (via an arterial line) to
manage shock patients. This opinion differs significantly from the opinions of several
other clinicians who stated that the sensitivity and specificity of the current technologies
is extremely low, making the technologies insufficient. While sensitivity and specificity
are both important, the sensitivity of the monitoring technologies is of particular
importance in the monitoring of patients that are at risk of going into shock because the
risks associated with not resuscitating a patient that is going into shock (false negatives)
far outweigh the risks associated with resuscitating a patient that is not going into shock
(false positives).
There are several reasonable explanations for why clinicians are more satisfied with the
monitoring of patients that are being resuscitated from shock. The clinician already
knows that there is a problem, so there is not a risk of missing the patient's declining
health status. However, while the clinician may know that the patient went into shock, it
may not be clear if the patient has been sufficiently resuscitated from shock. For this
reason, the specificity of the technology is critically important when monitoring patients
that are being resuscitated from shock. Another possible explanation for the higher
satisfaction level is that there are well developed protocols for resuscitation that are
widely used by clinicians, so the clinician's response to a patient in shock is standardized.
It is also worth noting that clinicians' satisfaction with the current technologies could be
due to the fact that they do not miss what they do not have. Finally, I should
acknowledge that I spoke with clinicians at some of the country's leading hospitals. One
of the interviewees explained that he has access to almost any technology he wants
because he works at a premier hospital. These hospitals and clinicians have access to
more advanced technology than clinicians at a majority of the nation's hospitals.
What is the Biggest Challenge in Monitoring and Treating Shock Patients?
Several clinicians discussed the challenge of discovering the underlying cause of a
patient's hypotension and hypoperfusion, especially in rapidly declining patients. In
many cases, clinicians do not know if a patient's low blood pressure is a serious problem.
Since there are not good surrogates for measuring the hypoxia of local tissue beds, they
do not know what is happening at a cellular level in different parts of the body. This
makes it extremely difficult for a clinician to know when to stop an intervention or when
to change directions. In some cases, clinicians retreat into a "cover your ass" mentality
or a "'are we practicing within the standard of care" mentality rather than tailoring their
interventions to address the perceived needs of a particular patient. In the emergency
room, clinicians have additional challenges. If a patient arrives at the ER in shock, the
clinician has very little time to intervene and sometimes it is already too late. One
clinician summarized the challenges of monitoring shock patients by stating that the
current technologies are too invasive and complex, not continuous, and do not provide an
accurate indication of the patient's status.
Desired Improvements in Monitoring
Even though some clinicians are fairly satisfied with the current monitoring technologies,
all of the clinicians are looking for improvements. When I asked if an earlier warning
would change the patient's outcome, I learned that an earlier warning is less important
that an accurate warning. In shock monitoring, an accurate warning would alert
clinicians that the patient's compensatory system is no longer able to perfuse the body's
tissues and it would also let clinicians know when a patient has been sufficiently
resuscitated. Therefore, the monitoring technology would need to be more sensitive and
specific than the currently available technologies. Since the risk associated with
resuscitating a patient that is not going into shock is lower than the risk associated with
not resuscitating a patient that is going into shock, false positives can be tolerated, while
false negatives are unacceptable.
One of the limitations of the current monitoring technologies is that the currently
available surrogates are not very sensitive or specific to shock. It would be extremely
valuable for a clinician to be able to accurately monitor tissue oxygenation. This would
help clinicians to determine when to begin or end treatment and it might help to
determine the underlying cause of the shock state. It should be noted that while an
earlier, more accurate warning would be valuable, it is difficult to quantify how much
earlier or more accurate would be necessary to alter a particular outcome because the
outcome generally depends on the underlying disease process.
Not surprisingly, several desired improvements differ depending on the environment
where the patient is being monitored and treated. In the ER, clinicians typically rely on
blood pressure, heart rate, and pulse oximetry because more invasive monitoring
technologies take time to insert and the resulting data do not provide enough incremental
benefit to justify the required time. In the ambulance, paramedics do limited monitoring
and rarely intervene because of evidence that these interventions do not improve
outcomes [12]. ER and ambulatory clinicians are looking for non-invasive monitoring
technologies that are quick and easy to calibrate and provide continuous feedback to help
the clinicians determine the status of a patient and if a particular intervention is working.
In the OR and the ICU, clinicians generally use more extensive monitoring technologies,
but tissue oxygenation and perfusion data are not available. A combination of the Swan-
Ganz catheter or a central venous catheter, pH, and lactate provide the closest estimate to
tissue oxygenation. Less invasive monitoring of the current parameters would be useful,
but a more sensitive and specific marker of tissue injury would be much more valuable.
Value of a Tissue Perfusion Monitor
I ended the interviews by asking clinicians to rate the value of a real-time, continuous,
tissue perfusion monitoring device in the management of shock patients. The
overwhelming consensus is that this type of technology would be extremely valuable. In
fact, for patients at risk of shock and patients being resuscitated from shock, the value of
a tissue perfusion monitoring was given a mean rating of 6 out of a possible 7, with a
standard deviation of 1.1.
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A continuous, real-time tissue perfusion monitor would be valuable for patients that are at
risk of shock and for patients that are being resuscitated from shock. For patients who
are not in shock or progressing towards shock, it would be useful to know that their
tissues are not in danger. A tissue perfusion monitor would also allow clinicians to
provide more precise resuscitation. One clinician gave me a recent example of a patient
who would have benefited from a tissue perfusion monitor. A young man, in his 20's,
was stabbed multiple times in the chest and neck. His heart, carotid artery, and
saphenous vein were punctured. The paramedics transported him to the emergency room,
reporting that he had lost vital signs at the scene and had likely been without vital signs
for about 15 minutes. The emergency room clinicians believed that the patient would be
brain-dead and as a result, a majority of the team did not support the resuscitation of this
patient. While the clinician who I interviewed agreed that the patient could not be saved,
he believed that resuscitation was warranted because the patient's organs could be
donated to other patients, thereby saving several lives. The patient underwent extensive
surgery and resuscitation before being brought to the ICU. When the clinician returned
to the ICU the next day to check on the patient's status, he touched the patient's shoulder
and the patient opened his eyes. The patient fully recovered from his injuries with no
permanent brain damage or other tissue injury. The clinician who I interviewed believes
that an accurate tissue perfusion monitor would have alerted the clinicians that the
patient's tissues were still viable and the decision to resuscitate him would not have been
challenged. In this particular case, the outcome would not have changed, but if the
patient had been older, or if it had been a different clinician, the team might not have
attempted resuscitation and the patient could have lost his life.
Criteria for a Tissue Perfusion Monitor
While the clinicians agreed that a tissue perfusion monitor would be valuable, they each
expanded upon their rating by stating that the device would need to meet a number of
additional criteria. First, it would need to measure the perfusion of one or multiple tissue
beds that are relevant to the shock condition. Second, the tissue perfusion monitor would
need to be more sensitive and specific than the current monitoring technologies. Third, it
would need to be clinically relevant and easy to use. Finally, the device would need to be
flexible enough to be used for a variety of different patients and in a variety of different
environments.
There is consensus that a tissue perfusion monitor would need to measure the perfusion
of a meaningful tissue. The brain, heart, kidney, and gut were mentioned by several
clinicians. These tissues are believed to be much better markers for shock than the skin
or muscle. One clinician stated that a tissue perfusion monitor would be most useful in
cases where there is a specific organ that is at risk. For example, perfusion of the kidney
would be extremely helpful in predicting renal failure after a complex surgery. While it
might be possible to identify one relevant tissue bed, some clinicians believe that the
perfusion of multiple tissue beds would be necessary to detect when the body's
autoregulation is no longer sufficient.
The tissue perfusion monitor would need to be more sensitive and specific than the
current monitoring technologies, providing better feedback to clinicians. Today,
clinicians rely on blood pressure, heart rate, blood gases, and urine output to indicate if a
patient is responding to a therapeutic intervention. These parameters are not sensitive or
specific to shock.
A tissue perfusion monitor would need to be easy to use, providing both an absolute
value and trends, and it would need to provide a clinically meaningful value in order for
clinicians to be willing to adopt the technology. To be clinically meaningful, the tissue
perfusion monitor needs to display the perfusion in units that the clinician can
understand. The clinicians also stated that the monitor would need to have well-
established thresholds to indicate when a patient is in danger or when a patient has been
sufficiently resuscitated. A non-invasive monitor would be the most useful, but clinicians
stated that a minimally invasive technology could be successful if the information was
shown to be extremely valuable.
Finally, the tissue perfusion monitor would need to work in a variety of different
situations and environments. For example, it would need to function for obese or
edematous patients and when the patient's autoregulatory system is vasoconstricting flow
away from the periphery. It would also need to function in the emergency room, in the
operating room, and in the intensive care unit, and it would ideally be able to travel with
the patient, so that trends could be captured for the patient's entire time in the hospital.
At the end of the day, the utility of a tissue perfusion monitor needs to be supported by
outcome data in animal models or humans.
Chapter 6: Implications
The literature and interviews validate the need for better shock monitoring technologies.
However, to ensure adoption, new technologies will need to address the limitations of the
current monitoring technologies.
Clinical Factors
Sensitivity and specificity, clinical relevance, and ease-of-use are critical factors that will
drive market adoption.
* Sensitivity and Specificity: The currently available technologies are not
sensitive or specific to shock. Rather, they measure systemic parameters that are
believed to roughly correlate with tissue perfusion and oxygenation. While
sensitivity and specificity are both important, their relative importance depends
whether the patient is at risk of shock or being resuscitated from shock.
Sensitivity is more important in the diagnosis of shock because the risks
associated with not diagnosing a patient that is going into shock far outweigh the
risks associated with resuscitating a patient that is not going into shock.
Specificity is more important in the resuscitation from shock because the clinician
needs to be absolutely certain that the patient has been sufficiently resuscitated
from shock. An improved shock monitoring technology will be more sensitive
and specific, accurately detecting when a patient is going into shock and when a
patient has been sufficiently resuscitated from shock.
* Clinical Relevance: In the context of shock monitoring technologies, clinical
relevance has several meanings, but the ultimate goal is to improve patient
outcomes. An improved shock monitoring technology should measure a
parameter that the clinician understands physiologically. The measurement
should be absolute and it should be provided in units that are meaningful. And
finally, the parameter should have thresholds that are fairly consistent across a
diverse patient population. Ideally, an improved shock monitoring technology
would measure the instantaneous state of tissue perfusion or tissue oxygenation as
well as the cumulative oxygen deficit.
Ease-of-Use: With so many available monitoring technologies, ease-of-use is an
important consideration. Non-invasive technologies are preferable, but a
minimally invasive technology will be adopted if it provides information that is
superior to the information available from the current technologies. In addition to
invasiveness, the set-up and configuration requirements are critical to the success
of a new monitoring technology. Several technologies, including gastric
tonometry, failed to receive widespread adoption because of the time required to
insert and configure the device.
While each of these characteristics are important, their relative importance differs
depending on the clinical setting in which the device will be used. For example, in the
emergency room and ambulance, ease of use is extremely important because patients are
being moved around for multiple tests and clinicians do not have time to wait for a device
to calibrate. In contrast, patients in the operating room and intensive care unit are not
being moved and there is generally more time to insert and calibrate a device. There is
also a higher tolerance for invasive monitoring technologies in the operating room and
intensive care unit.
Market Factors
The dynamics of the patient monitoring market will play an important role in driving
adoption of a new monitoring technology. In the multiparameter patient monitoring
market, there is a trend towards telemetry and central monitoring [9]. These
enhancements make it easier for clinicians to monitor multiple patients simultaneously.
An improved shock monitoring technology will be more widely adopted if it can be
integrated into an existing monitoring platform. There are several benefits to the
development of a module, versus a stand-alone monitoring technology. For example, if a
hospital does not need to purchase additional capital equipment, the purchasing decision
will be much easier. Additionally, clinicians would appreciate a reduction in the wires
and devices that surround a patient. And finally, as hospitals standardize their monitoring
technologies to optimize training and enhance continuity of care, they will be inclined to
choose technology platforms that can incorporate many different monitoring parameters.
Companies interested in entering the patient monitoring market should consider
partnering with one of the existing players. Philips Medical Systems and GE Healthcare
are the leading players, representing over 70% of the hospital vitals signs patient
monitoring market [9]. Appendix B contains a list of patient monitoring companies and
their respective product lines.
Clinical Trial Design
Companies must design clinical trials that will enable them to demonstrate clinical utility
in the crowded shock monitoring market. They must choose the type(s) of shock, the
clinical environment, the comparative parameter(s), and whether to target their trial at the
diagnosis of shock or the resuscitation from shock. As a company considers the most
appropriate clinical trial design, ethical issues, such as obtaining informed consent, are
also important.
Type of Shock
Hypovolemic shock is the most common type of shock and the mechanism is well
understood. Distributive shock is also quite common, but the underlying mechanism and
natural history are more complex. This complexity could make it more difficult to
demonstrate an improvement in shock monitoring. Since cardiogenic shock is caused by
a cardiac defect that prevents the heart from pumping sufficiently, the current
technologies that measure cardiac output or provide images of the heart are probably
sufficient.
Clinical Environment
The challenges and opportunities associated with shock monitoring differ depending on
the environment where the monitoring occurs. For example, there might be a lower bar
for demonstrating the utility of a monitoring technology in the emergency room than in
the intensive care unit because fewer monitoring technologies are used in the emergency
room. However, the challenges associated with the design of a randomized controlled
trial, including the challenge of informed consent, in the emergency room make a trial in
this environment impractical [5]. To increase the probability of success, companies
should conduct their clinical trials in the clinical environment with the lowest risk profile.
Comparative Parameters
Since there is not a perfect surrogate for shock, companies should consider comparing
new monitoring technologies to several of the parameters that are measured by the
currently available technologies. Companies should choose comparative parameters that
are widely used and believed to be reasonable surrogates for tissue perfusion and
oxygenation, such as mixed venous oxygen saturation, pH, and lactate. While companies
will eventually hope to establish superiority over the current monitoring technologies,
non-inferiority trials will need to be completed first. If the monitoring technology is less
invasive or easier to use than the comparator technology, favorable results from a non-
inferiority trial could be sufficient to drive market adoption.
Diagnosis or Resuscitation?
There is a clinical need for improved technologies to monitor patients that are at risk of
going into shock and patients that are being resuscitated from shock. Today, many of the
same technologies are used for both patient populations. However, companies should
choose the most appropriate patient population for conducting a clinical trial. If the trial
were designed to diagnose shock patients, it would require an extremely large patient
population because only a small percent of the patients would ultimately go into shock.
However, if the trial were designed to monitor the resuscitation of shock patients, a
smaller patient population would be sufficient to demonstrate the benefits of the new
monitoring technology. The sensitivity and specificity of the new technology should also
guide the selection of an appropriate patient population because sensitivity is more
important for the diagnosis of shock and specificity is more important for the monitoring
of resuscitation from shock.
Recommendation
The interviews and research highlight several important factors that can guide the clinical
trial design for new shock monitoring technologies. Hypovolemic shock is the most
logical choice for a clinical trial because it is the most common form of shock and the
mechanism is well understood. To minimize the risks associated with the clinical
environment, companies should conduct their trials in the intensive care unit, where
clinicians have the time to conduct extensive monitoring. Since there is not one ideal
surrogate marker for shock, companies should choose comparative parameters that are
widely used and believed to be reasonable surrogates for tissue perfusion and
oxygenation. Mixed venous oxygen saturation or central venous oxygen saturation,
lactate, and pH are the most logical choices because these parameters are believed to
provide the closest approximation to what is happening at the tissue level. However, for
completeness, it would also be useful to correlate the findings with systemic parameters,
such as heart rate and blood pressure. And finally, based on the cost and time
requirements, companies should design their clinical trials to monitor the resuscitation of
shock patients.
Chapter 7: Summary
Conclusions
The goal of this research was to characterize the current shock monitoring and
management techniques and to analyze the need for an improved shock monitoring
technology. In order to better ascertain if the current monitoring technologies are
adequate, I defined the standard of care for monitoring patients that are at risk of going
into shock and for monitoring patients that are being resuscitated from shock.
I developed a hypothesis that the limitations of current monitoring technologies
contribute to the high mortality rate associated with shock. To empirically assess my
hypothesis, I conducted an extensive review of the scientific literature and I interviewed
nine clinicians and three scientists. The scientific literature identified the challenges of
preventing and managing shock and described the currently available monitoring
technologies. The interviews were particularly insightful because they highlighted the
clinicians' perceptions about the monitoring technologies and provided me with an
understanding of how the current technologies are used in combination with each other.
The interviews also alerted me to the other non-monitoring challenges that are associated
with the management of shock patients.
Despite the large number of technologies available to monitor patients, shock continues
to be a life threatening condition. While there are several factors driving the high
mortality rate from shock, this research confirms my hypothesis that the limitations of the
current shock monitoring technologies play a significant role.
There is a clinical need for improved shock monitoring technologies. However, for a
new technology to attain market adoption, it will need to address and overcome the
limitations of the current technologies. A monitoring technology is only valuable if it
enables clinicians to better manage patients and improve outcomes. Very few of the
current shock monitoring technologies have been able to consistently demonstrate
improved patient outcomes. In the case of shock monitoring, clinicians believe that the
measurement of regional tissue perfusion or oxygenation would more accurately predict
when a patient is going into shock or when a patient has been sufficiently resuscitated
from shock.
Limitations
My thesis research demonstrates that there is need for improved shock monitoring
technologies. However, there are limitations to my research that must be acknowledged.
The biggest limitation is the small number of interviews that I conducted with clinicians
and scientists. A more comprehensive analysis would have included a large number of
clinicians who work in each clinical environment and it would have included clinicians
working at community hospitals in addition to academic medical centers. Another
limitation is the interview guide itself. Since I conducted one hour interviews, I was
limited in the number of questions that I could ask the clinicians. A longer interview,
with more detailed questions, would have provided additional insights for a company
interested in launching a new monitoring technology. For example, I would have asked
questions about clinical trial design and the data clinicians would need to see before
deciding to purchase and use the device. I also would have asked questions about the
clinicians' willingness to pay for an improved shock monitoring technology. And finally,
while I conducted extensive background research, I was not able to read every
publication relevant to shock monitoring and management. As a result, I may have
inadvertently excluded information that is relevant to a company's decision to enter this
market.
Future Research
While the interviews and research provide insights that can guide the clinical trial design,
additional data is needed to validate the recommendations and the needs of the market.
Clinical Need
What patients would benefit the most from an improved shock monitoring technology?
What clinical trial endpoints are necessary to demonstrate clinical utility for these
patients?
The Army Institute for Surgical Research has a Trauma Vitals Program that collects data
on trauma patients transported to the emergency room by helicopter. Nurses correlate
this data with the outcomes in the hospital. This group is also creating a database with
the vital signs of healthy volunteers subjected to a negative pressure chamber. These
databases would be helpful in validating where the clinical need is the greatest.
Additional data may be available from the Society of Critical Care Medicine or the
Institute of Critical Care Medicine.
Market Opportunity
What are the economics of shock monitoring and management? Do the economics vary
depending on the type of shock or the clinical environment where the shock patients are
being managed?
A follow-up survey might be necessary to clarify the interview results and better
delineate how much the market is willing to pay for an improved shock monitoring
technology. Based on the research and interviews, it is not clear how hospitals would
value an improved shock monitor. It is also not clear if the value is the same for the
different types of shock and the different clinical environments. Hospitals have
committees that are responsible for assessing the need for new devices and approval by
the committee is necessary before clinicians are permitted to purchase and use a new
device. This can pose a significant challenge for a company interested in penetrating the
hospital market because committee approval typically requires a Key Opinion Leader
within the hospital to act as product champion. These product champions make the case
for the device and shepherd the device through the process. Companies should not
underestimate the need for one or multiple product champions and should actively work
to develop collaborative relationships with Key Opinion Leaders.
Appendix A: Interview Guide
Patients at Risk of Shock
* How do you define shock?
* What types of patients are at risk of going into sudden shock?
o Can you break it down by the different types of shock?
o What criteria are used to determine if a patient is at risk?
o Of those at risk, what percent ultimately go into shock?
* How are patients that are at risk of shock managed?
o Who makes the decision (physician, nurse, other)?
o Where does this management occur (ER, OR, ICU, patient's room, etc.)?
o What monitoring technologies are used and in what combination?
* Does it vary depending on the type of shock a patient is at risk of?
o What parameters are most useful in detecting when a patient is going into
shock?
* What provides the earliest indication?
* Can you describe any limitations of these products?
o When do you intervene?
* What interventions are used for each type of shock?
* How has this changed over time?
* What goes wrong and why?
o What do you do and what's the outcome?
* Would an earlier warning of a patient's entry into shock change the management
or outcome?
o How much earlier would be necessary? How would the treatment or
outcome change?
* In general, how has the management of patients at risk of going into shock
changed over time?
Patients in Shock
* What criteria do you use to determine if a patient is in shock?
o Does this vary based on the type of shock?
* How do you manage patients that are in shock?
o How does it vary depending on the type of shock?
o What monitoring technologies are used and for what purposes?
* Can you describe any limitations of these technologies?
o For what indications is fluid resuscitation appropriate?
* What fluids are administered and in what situations?
* How are the fluids administered? Protocol?
* What endpoints are used to confirm adequate fluid resuscitation?
* What goes wrong and why?
o What do you do and what's the outcome?
* Would an improved measurement of tissue perfusion change the management or
outcome of patients that are in shock?
o How would the treatment or outcome change?
* On a scale of 1-7, how satisfied are you with how you monitor and treat:
o Patients at risk of going into shock?
o Patients that are in shock?
* What is the biggest problem that you have in monitoring and treating these
patients?
* Are you aware of any new technologies to improve monitoring of these patients?
o What about technologies that were not successful?
* Can you rate on a scale of 1-7, the value of a real-time, continuous, and absolute
tissue perfusion monitor for:
o Monitoring patients at risk of going into shock?
o Monitoring of patients in shock?
* Any other comments?
Appendix B: Patient Monitoring Companies
* Analogic
o Products include digital radiography, fetal monitors, imaging subsystems,
computed tomography, patient monitors, and airport security systems
* CAS Medical Systems
o Products include patient monitoring, cerebral oximetry, mother/baby
monitoring, blood pressure cuffs & supplies, and non-invasive blood
pressure monitoring technology (for OEMs)
* Colin Medical Technology Corporation (an OMRON Company)
o Products include portable vital sign monitors and multiparameter monitors
* Criticare Systems, Inc.
o Products include pulse oximeters, vital signs monitors, anesthesia/OR
monitors, and central station systems
* Datascope
o Products include bedside and central monitors
* Draeger Medical
o Products include anesthesia workstations, patient monitoring, central and
bedside workstations, telemetry and wireless monitoring, jaundice
management, ventilation, and warming therapy
* Fukuda Denshi
o Products include electrocardiographs, bedside and central patient
monitors, and ultrasound technology
* GE Healthcare
o Products include a full line of patient monitoring systems
* Mennen Medical
o Products include patient monitoring, radiology, hemodynamic monitoring,
and non-invasive temperature management systems
* Mindray
o Products include patient monitoring, anesthesia, diagnostic laboratory
instruments, and ultrasound systems
* Nihon Kohden
o Products include bedside and central monitors, pulse oximeter, SpO2/CO2
monitor, electroencephalograph, evoked potential/EMG system,
hematology analyzer
* Phillips Medical Systems
o Products include x-ray, ultrasound, MRI, computed tomography, nuclear
medicine, information management, and resuscitation
* Schiller AG
o Products include pulse oximetry and transport monitoring
* Spacelabs Healthcare
o Products include patient monitors, anesthesia and ventilation, and
diagnostic cardiology products
* Welch Allyn
o Products include continuous patient monitoring and automated vitals signs
capture
Appendix C: References
1. Bernard GR, Sopko G, Cerra F, Demling R, Edmunds H, Kaplan S, Kessler L,
Masur H, Parsons P, Shure D, Webb C. "Pulmonary Artery Catheterization and
Clinical Outcomes - National Heart, Lung, and Blood Institute and Food and
Drug Administration Workshop Report." JAMA. 2000;283(19):2568-2572.
2. Cohn SM, Nathans AB, Moore FA, Rhee P, Puyana JC, Moore EE, Beilman GJ.
"Tissue Oxygen Saturation Predicts the Development of Organ Dysfunction
During Traumatic Shock Resuscitation." American Association for the Surgery
of Trauma Annual Meeting. September 2006.
3. Dorland's Medical Dictionary
4. Dutton, Richard. "Chapter 3 - Shock Management." Pending publication.
5. Dutton RP, Stansbury LG, Hemlock B, Hess JR, Scalea TM. "Impediments to
Obtaining Informed Consent for Clinical Research in Trauma Patients." Journal
of Trauma Injury, Infection, and Critical Care. 2008;64:1106-1112.
6. Gaieski D, Manaker S. "General evaluation and differential diagnosis of shock in
adults." UpToDate 2007.
7. Gomersall CD, Joynt GM, Freebaim RC, Hung V, Buckly TA, Oh TE.
"Resuscitation of critically ill patients based on the results of gastric tonometry: a
prospective, randomized, controlled trial." Critical Care Medicine.
2000;28(3):607-614.
8. Grace PA. "Ischaemia - reperfusion injury." British Journal of Surgery.
1994;81"637-647.
9. Healthcare Group. "U.S. Multiparameter Monitoring Market." Frost & Sullivan.
August 2005.
10. Healthcare Services Group. "Coding and Documentation - 2008 Update." Amper
Politziner & Mattia. 2008.
11. Hoyt DB. "Fluid Resuscitation: The Target from an Analysis of Trauma Systems
and Patient Survival." Journal of Trauma. 2003;54: S31-S35.
12. Kwan I, Bunn F, Roberts I, on behalf of the WHO Pre-Hospital Trauma Care
Steering Committee. "Timing and volume of fluid administration for patients with
bleeding." Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.:
CD002245.
13. Landry DW, Oliver JA. "Insights into Shock." Scientific American.
2004;290(2):36-41.
14. Libeman M, Mulder D, Sampalis J. "Advanced or Basic Life Support for Trauma:
Meta-analysis and Critical Review of the Literature." Journal of Trauma, Injury,
Infection, and Critical Care. 2000;49(4):584-599.
15. Madan AK, UyBarreta VV, Aliabadi-Wahle S, et al. "Esophageal Doppler
ultrasound monitor versus pulmonary artery catheter in the hemodynamic
management of critically ill surgical patients." Journal of Trauma. 1999;46:607-
611.
16. Maier RV. "Chapter 264. Approach to the Patient with Shock." Harrison's
Principles of Internal Medicine. 17th Edition. 2008.
17. Merck Manual of Medical Information - Second Home Edition
18. Molyneux EM, Maitland K. "Intravenous Fluids - Getting the Balance Right."
New England Journal of Medicine. 2005;353(11):941-944.
19. National Heart Lung and Blood Institute,
http://www.nhlbi.nih.gov/health/dci/Diseases/shock/shock what.html
20. Otero R, Garcia AJ. "Clinical review: New technologies - venturing out of the
intensive care unit." Critical Care. 2005;9(3):296-302.
21. Peralta R. "Shock, Distributive." Emedicine from WebMD. October 3, 2006.
22. Pinskey, Michael R. "Hemodynamic monitoring over the past 10 years." Critical
Care Medicine. 2006;10:117.
23. Pinskey MR, Vincent J-L. "Let us use the pulmonary artery catheter correctly and
only when we need it." Critical Care Medicine. 2005;33(5):1119-1122.
24. Porter JM, Ivatury RR. "In Search of the Optimal End Points of Resuscitation in
Trauma Patients: A Review." Journal of Trauma. 1998;44(5):908-914.
25. Rady MY. "Bench-to-bedside review: Resuscitation in the emergency
department." Critical Care. 2005;9(2):170-176.
26. Richard C, Warszawski J, Anguel N, Deye N, Comes A, Barnoud D, Boulain T,
LeFort Y, Fartoukh M, Baud F, et al. "Early use of the pulmonary artery catheter
and outcomes in patients with shock and acute respiratory distress syndrome: a
randomized controlled trial." JAMA. 2003;290(20):2713-2720.
27. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E,
Tomlanovich M. "Early Goal-Directed Therapy in the Treatment of Severe Sepsis
and Septic Shock." The New England Journal of Medicine. 2001;345(19):1368-
1377.
28. Rubenfeld GD, McNamara-Aslin E, Rubinson L. "The Pulmonary Artery
Catheter, 1967-2007: Rest in Peace?" JAMA. 2007;298(4):458-461.
29. Scheer BV, Perel A, Pfeiffer UJ. "Clinical review: Complications and risk factors
of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia
and intensive care medicine." Critical Care. 2002;6(3):198-204.
30. Soller BR, Ryan KL, Rickards CA, et al. "Oxygen saturation determined from
deep muscle, not thenar tissue, is an early indicator of central hypovolemia in
humans." Critical Care Medicine. 2008;36(1):176-182.
31. Springhouse. "Professional Guide to Diseases (Eighth Edition)." Lippincott
Williams & Wilkins. 2005.
32. Staylor, Anne. "Hemodynamic Monitoring Enters a New Era." Medtech Insight.
2008 Windhover Information Inc.
33. Wiener RS, Welch HG. "Trends in the Use of the Pulmonary Artery Catheter in
the United States, 1993-2004." JAMA. 2007;298(4):423-429.
34. Wilson, Lynn. "The Medical & Healthcare Marketplace Guide." 19th edition.
Dorland Healthcare Information, 2004.
35. www.hemedex.com
36. www.htibiomeasurement.com/technology.asp
37. www.umm.edu/shocktrauma/historv.htm
